Evidence map›Paper›PMID 25471526›Full record

ArticleVirology journal2014

E5564 inhibits immunosuppressive cytokine IL-10 induction promoted by HIV-1 Tat protein.

Elmostafa Bahraoui, Laurence Briant, Nathalie Chazal

Open access · goldAbstract read
In one paragraph

Article in Virology journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Elmostafa BahraouiUniversité Paul Sabatier, EA 3038, 118 Route de Narbonne, 31062, Toulouse, France. bahraoui@cict.fr.
Laurence BriantCentre d'études d'agents Pathogènes et Biotechnologies pour la Santé (CPBS), UMR5236, CNRS - Université Montpellier 1-Montpellier 2, Montpellier, France. laurence.briant@cpbs.cnrs.fr.
Nathalie ChazalCentre d'études d'agents Pathogènes et Biotechnologies pour la Santé (CPBS), UMR5236, CNRS - Université Montpellier 1-Montpellier 2, Montpellier, France. nathalie.chazal@cpbs.cnrs.fr.
Centre d’études d’agents Pathogènes et Biotechnologies Pour la Santé · FRCentre Hospitalier Universitaire de Toulouse · FRInstitut de Recherche en Infectiologie de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn HIV-1 infected patients, production of interleukin-10 (IL-10), a highly immunosuppressive cytokine, is associated with progression of infection toward AIDS. HIV-1 Tat protein, by interacting with TLR4-MD2 at the membrane level, induces IL-10 production by primary human monocytes and macrophages. In the present study we evaluated the effect of the TLR4 antagonist Eritoran tetrasodium (E5564) on HIV-1 Tat-induced IL-10 production.

findingsHere, we confirm that the recombinant HIV-1 Tat protein and the GST-Tat 1-45 fusion protein efficiently stimulate IL-10 production by primary monocytes and macrophages and that this stimulation is inhibited by blocking anti-TLR4 mAbs. We show that a similar inhibition is observed by preincubating the cells with the TLR4 antagonist E5564.

conclusionThis study provides compelling data showing for the first time that the TLR4 antagonist E5564 inhibits the immunosuppressive cytokine IL-10 production by primary human monocytes and macrophages incubated in the presence of HIV-1 Tat protein.

Indexed as

Gene Products, tatHIV-1HumansImmunologic FactorsInterleukin-10Lipid AMacrophagesMonocytesToll-Like Receptor 4E5564Gene Products, tatImmunologic FactorsInterleukin-10Lipid ATLR4 protein, humanToll-Like Receptor 4

Identifiers

PMID25471526
PMCPMC4267154
OpenAlexW1978155748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.